Skip to content
Companies

Chimeron Bio

Self-amplifying RNA medicines and vaccines

Raised to date

$12.8M

across 1 Form D filing

Investors
9
Last filed
Mar 14, 2025

About

Chimeron Bio Corp is a forward-thinking biotechnology company headquartered in Philadelphia, focused on the innovation of RNA-based therapeutics and vaccines. Through its proprietary ChaESAR™ platform, the company seeks to enhance the effectiveness of RNA medicines by leveraging self-amplifying RNA technology to create treatments that are more potent and long-lasting than traditional mRNA solutions.

Chimeron Bio stands out with its ChaESAR™ platform, which significantly improves the potency and duration of RNA-based therapies while simplifying the manufacturing process.

Funding

  • EquityFiled Mar 14, 2025Form D/A
    $12.8M/ no target

Product

ChaESAR™ Platform

Biotechnology Platform

The ChaESAR™ platform is a proprietary technology that employs self-amplifying RNA (saRNA) to develop potent RNA-based therapeutics and vaccines. This platform enhances the efficacy and longevity of treatment effects while reducing the necessary dosage and simplifying the production and distribution processes.

  • Self-amplifying RNA technology
  • Increased potency compared to traditional mRNA
  • Longer-lasting therapeutic effects

Built for

Pharmaceutical companies and healthcare providers

People on file